^
Association details:
| Biomarker: | PD-L1 underexpression |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug Class: | PD-L1 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Factors Modifying the Associations of Single or Combination Programmed Cell Death 1 and Programmed Cell Death Ligand 1 Inhibitor Therapies With Survival Outcomes in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis
Published date:
01/04/2021
Excerpt:
...treatment response to PD-1/PD-L1 inhibitors in patients with metastatic ccRCC was significantly associated with age (OS: ratio of HR for age ≥75 years to HR for age <65 years, 1.51; 95% CI, 1.01-2.26), PD-L1 expression (PFS: ratio of HR for PD-L1 < 1%...This analysis suggests that older age, low levels of PD-L1 expression, and the absence of sarcomatoid tumor differentiation are associated with a diminished response to anti-PD-1/PD-L1 immunotherapies with respect to survival outcomes among patients with metastatic ccRCC.
DOI:
10.1001/jamanetworkopen.2020.34201.
